Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
Brief Summary: The purpose of this study in HCV genotype 4-infected participants with compensated cirrhosis is to assess the safety and to compare the percentage of participants achieving a 12-week sustained virologic response (SVR12), \[HCV ribonucleic acid (RNA) \< lower limit of quantification (LLOQ) 12 weeks following treatment\], to a clinically relevant threshold \[based on SVR rates for HCV genotype 4-infected participants treated with pegylated interferon (pegIFN)/RBV\].


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Intervention Type: DRUG; Name: ombitasvir/paritaprevir/ritonavir; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D
B: Arm Label: SOF/VEL; Type: EXPERIMENTAL; Interventions: Drug: SOF/VEL | Arm Label: SOF+RBV; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF/VEL; Assigned to Arm(s): SOF/VEL | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C
D: Arm Label: Treatment A: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment B: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment C: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment D: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment E: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment F: PSI-7977 + Daclatasvir+ Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment G: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment H: PSI-7977 + BMS-790052 + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment I: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment J: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Intervention Type: DRUG; Name: PSI-7977; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment J: PSI-7977 + Daclatasvir + Ribavirin

Answer: A